Okta, Inc. <OKTA.O>: UBS Raises Target Price to $200 From $150
OKTA•Related News
enVVeno Medical wins FDA IDE approval for enVVe pivotal trial in deep venous insufficiency
NVNO•
CrowdStrike Holdings, Inc. <CRWD.O>: UBS Raises Target Price to $250 From $235
CRWD•
Jobless claims dip in latest week; goods trade deficit widens in July
SPY•
Kearny Bank provides $7.3 million refinance loan for 114-unit Waterbury, Connecticut apartment building
KRNY•
Fiserv CEO, CFO to speak at Goldman Sachs Communacopia + Technology Conference
FI•